Loading...

Valens GroWorks

DB:7LV
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
7LV
DB
CA$434M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Valens GroWorks Corp., a biotechnology company, engages in the scientific research of phytopharmaceutical material primarily producing cannabis and cannabis related products. The last earnings update was 1 day ago. More info.


Add to Portfolio Compare Print
  • Valens GroWorks has significant price volatility in the past 3 months.
7LV Share Price and Events
7 Day Returns
12%
DB:7LV
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
197.4%
DB:7LV
-5.6%
DE Biotechs
-4.5%
DE Market
7LV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Valens GroWorks (7LV) 12% 44.4% 87% 197.4% - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 7LV outperformed the Biotechs industry which returned -5.6% over the past year.
  • 7LV outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
7LV
Industry
5yr Volatility vs Market

Value

 Is Valens GroWorks undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Valens GroWorks to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Valens GroWorks.

DB:7LV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:7LV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 26.5%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:7LV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Valens GroWorks is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:7LV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 8%)
2019 0.54 Analyst x1 0.50
2020 47.93 Analyst x1 41.10
2021 62.63 Analyst x1 49.73
2022 74.34 Est @ 18.7% 54.65
2023 84.13 Est @ 13.16% 57.26
2024 91.93 Est @ 9.28% 57.94
2025 97.96 Est @ 6.56% 57.17
2026 102.53 Est @ 4.66% 55.41
2027 105.95 Est @ 3.33% 53.02
2028 108.49 Est @ 2.4% 50.27
Present value of next 10 years cash flows CA$477.05
DB:7LV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CA$108.49 × (1 + 0.23%) ÷ (8% – 0.23%)
CA$1,399.73
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$1,399.73 ÷ (1 + 8%)10
CA$648.56
DB:7LV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$477.05 + CA$648.56
CA$1,125.60
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$1,125.60 / 108.67
CA$10.36
DB:7LV Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:7LV represents 0.62759x of CNSX:VGW
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.62759x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 10.36 x 0.62759
€6.50
Value per share (EUR) From above. €6.50
Current discount Discount to share price of €2.79
= -1 x (€2.79 - €6.50) / €6.50
57.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Valens GroWorks is available for.
Intrinsic value
>50%
Share price is €2.79 vs Future cash flow value of €6.5
Current Discount Checks
For Valens GroWorks to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Valens GroWorks's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Valens GroWorks's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Valens GroWorks's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Valens GroWorks's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:7LV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-02-28) in CAD CA$-0.23
CNSX:VGW Share Price ** CNSX (2019-04-25) in CAD CA$4.44
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Valens GroWorks.

DB:7LV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:VGW Share Price ÷ EPS (both in CAD)

= 4.44 ÷ -0.23

-19.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Valens GroWorks is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Valens GroWorks is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Valens GroWorks's expected growth come at a high price?
Raw Data
DB:7LV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
92.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Valens GroWorks, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Valens GroWorks's assets?
Raw Data
DB:7LV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-02-28) in CAD CA$0.53
CNSX:VGW Share Price * CNSX (2019-04-25) in CAD CA$4.44
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:7LV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:VGW Share Price ÷ Book Value per Share (both in CAD)

= 4.44 ÷ 0.53

8.31x

* Primary Listing of Valens GroWorks.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Valens GroWorks is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Valens GroWorks's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Valens GroWorks has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Valens GroWorks expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
92.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Valens GroWorks expected to grow at an attractive rate?
  • Valens GroWorks's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Valens GroWorks's earnings growth is expected to exceed the Germany market average.
  • Valens GroWorks's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:7LV Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:7LV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 92.5%
DB:7LV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 53.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:7LV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:7LV Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-11-30 207 1
2021-11-30 170 62 54 2
2020-11-30 122 50 37 4
2019-11-30 43 8 7 4
DB:7LV Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-02-28 2 -11 -19
2018-11-30 0 -9 -16
2018-08-31 0 -6 -9
2018-05-31 0 -5 -8
2018-02-28 0 -2 -7
2017-11-30 0 -2 -4
2017-08-31 0 -1 -11
2017-05-31 0 -1 -11
2017-02-28 0 -1 -9
2016-11-30 0 0 -8
2016-08-31 0 0 -1
2016-05-31 0 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Valens GroWorks's earnings are expected to grow significantly at over 20% yearly.
  • Valens GroWorks's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:7LV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Valens GroWorks Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7LV Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-11-30
2021-11-30 0.39 0.39 0.39 1.00
2020-11-30 0.27 0.32 0.22 2.00
2019-11-30 -0.01 -0.01 -0.01 1.00
DB:7LV Past Financials Data
Date (Data in CAD Millions) EPS *
2019-02-28 -0.23
2018-11-30 -0.22
2018-08-31 -0.14
2018-05-31 -0.13
2018-02-28 -0.12
2017-11-30 -0.08
2017-08-31 -0.13
2017-05-31 -0.14
2017-02-28 -0.15
2016-11-30 -0.16
2016-08-31 -0.05
2016-05-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Valens GroWorks will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Valens GroWorks's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Valens GroWorks has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Valens GroWorks performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Valens GroWorks's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Valens GroWorks does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Valens GroWorks's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Valens GroWorks's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Valens GroWorks's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Valens GroWorks Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:7LV Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-02-28 2.27 -18.50 15.08
2018-11-30 0.05 -15.91 12.59
2018-08-31 0.05 -9.32 9.21
2018-05-31 0.06 -8.05 8.38
2018-02-28 0.04 -7.28 7.62
2017-11-30 0.04 -4.38 4.76
2017-08-31 0.02 -11.44 4.30
2017-05-31 0.01 -10.61 3.42
2017-02-28 0.05 -9.08 1.93
2016-11-30 0.11 -8.33 1.21
2016-08-31 0.24 -0.67 1.03
2016-05-31 0.24 -0.86 1.00
2016-02-29 0.19 -0.72 0.89
2015-11-30 0.13 -0.59 0.71
2014-11-30 -0.45 0.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Valens GroWorks has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Valens GroWorks has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Valens GroWorks improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Valens GroWorks's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Valens GroWorks has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Valens GroWorks's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Valens GroWorks's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Valens GroWorks is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Valens GroWorks has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Valens GroWorks's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Valens GroWorks has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Valens GroWorks Company Filings, last reported 1 month ago.

DB:7LV Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-02-28 49.82 0.00 20.55
2018-11-30 52.71 0.00 25.23
2018-08-31 15.61 0.00 2.82
2018-05-31 17.65 0.00 5.10
2018-02-28 19.06 0.00 10.47
2017-11-30 7.21 0.86 0.29
2017-08-31 2.39 0.00 0.24
2017-05-31 -0.43 0.95 0.33
2017-02-28 -0.04 0.46 0.49
2016-11-30 -1.14 0.00 0.01
2016-08-31 -1.37 0.03 0.00
2016-05-31 -1.17 0.03 0.02
2016-02-29 -0.89 0.00 0.01
2015-11-30 -0.89 0.00 0.01
2014-11-30 -0.30 0.03 0.01
  • Valens GroWorks has no debt.
  • Valens GroWorks currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Valens GroWorks has sufficient cash runway for 1.2 years based on current free cash flow.
  • Valens GroWorks has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 115% each year.
X
Financial health checks
We assess Valens GroWorks's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Valens GroWorks has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Valens GroWorks's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Valens GroWorks dividends.
If you bought €2,000 of Valens GroWorks shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Valens GroWorks's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Valens GroWorks's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:7LV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:7LV Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2022-11-30
2021-11-30
2020-11-30
2019-11-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Valens GroWorks has not reported any payouts.
  • Unable to verify if Valens GroWorks's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Valens GroWorks's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Valens GroWorks has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Valens GroWorks's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Valens GroWorks afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Valens GroWorks has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Valens GroWorks's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andrew Robson
COMPENSATION CA$360,750
TENURE AS CEO 1.9 years
CEO Bio

Mr. Andrew Tyler Robson has been the Chief Executive Officer of Valens Groworks Corp. since May 04, 2017. Mr. Robson serves as Director of Operations at Valens Agritech Inc. He served as Chief Operating Officer of Valens Groworks Corp. from February 10, 2017 to May 04, 2017. As a Master Grower, Mr. Robson provides consulting services on plant genetics, growing methods and leading facility and soil grown techniques that ensures consistently produced medical marijuana of the highest quality. He has been a Director of Valens Groworks Corp. since April 29, 2016. He served as an Independent Director of Genovation Capital Corp. since April 29, 2016. Mr. Robson attended the University of Saskatchewan on a football scholarship, graduating with a Bachelor of Science degree to return to Kelowna to pursue research and development, plant innovation and life sciences, with an emphasis on medical cannabis and its applications in the treatment of seizures, chronic diseases, pain control and neurological symptoms.

CEO Compensation
  • Andrew's compensation has increased whilst company is loss making.
  • Andrew's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Valens GroWorks management team in years:

0.8
Average Tenure
  • The average tenure for the Valens GroWorks management team is less than 2 years, this suggests a new team.
Management Team

Andrew Robson

TITLE
CEO & Director
COMPENSATION
CA$361K
TENURE
1.9 yrs

Chris Buysen

TITLE
CFO & Director
TENURE
0.8 yrs

Chantel Popoff

TITLE
Chief Operating Officer

Everett Knight

TITLE
Executive Vice President of Strategy & Investments
TENURE
0.3 yrs

Scott Young

TITLE
Head of Investor Relations
TENURE
0.8 yrs

Kayla Mann

TITLE
Marketing Manager

Anderson Smith

TITLE
Head of Regulatory Affairs

Gord Fretwell

TITLE
Corporate Secretary
AGE
65
TENURE
2.4 yrs

Cynthia Lambert

TITLE
Controller

Dawn Visintainer

TITLE
Head of QA & QC Customer Service Rep - Valens Agritech
Board of Directors Tenure

Average tenure of the Valens GroWorks board of directors in years:

0.6
Average Tenure
  • The average tenure for the Valens GroWorks board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Buysen

TITLE
CFO & Director
TENURE
0.6 yrs

Rob O'Brien

TITLE
Director
TENURE
2 yrs

Andrew Robson

TITLE
CEO & Director
COMPENSATION
CA$361K
TENURE
3 yrs

Chris Irwin

TITLE
Director
AGE
44
TENURE
0.6 yrs

Nitin Kaushal

TITLE
Director
AGE
52
TENURE
0.6 yrs

Ashley McGrath

TITLE
Director
TENURE
0.6 yrs

Phillip Donne

TITLE
Member of Advisory Board
TENURE
0.5 yrs

Brett Channer

TITLE
Member of Advisory Board
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • Valens GroWorks insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
08. Apr 19 Sell Gordon Fretwell Individual 08. Apr 19 08. Apr 19 -10,000 €2.19 €-21,858
26. Mar 19 Sell 1009368 Bc Ltd. Company 06. Feb 19 06. Feb 19 -3,500,000 €1.37 €-4,780,795
23. Jan 19 Sell Gordon Fretwell Individual 22. Jan 19 22. Jan 19 -8,500 €1.60 €-13,570
05. Sep 18 Sell 1009368 Bc Ltd. Company 27. Aug 18 05. Sep 18 -1,126,562 €1.08 €-823,868
10. May 18 Sell David Gervais Individual 08. May 18 09. May 18 -10,000 €0.91 €-9,009
X
Management checks
We assess Valens GroWorks's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Valens GroWorks has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Valens GroWorks Corp., a biotechnology company, engages in the scientific research of phytopharmaceutical material primarily producing cannabis and cannabis related products. It is also involved in the analytical laboratory testing of cannabis. The company has collaborative research partnerships with UBC Okanagan and Thompson Rivers University. Valens Groworks Corp. is headquartered in Kelowna, Canada.

Details
Name: Valens GroWorks Corp.
7LV
Exchange: DB
Founded:
CA$288,464,360
108,665,086
Website: http://www.valensgroworks.com
Address: Valens GroWorks Corp.
230 Carion Road,
Kelowna,
British Columbia, V4V 2K5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX VGW Common Shares Canadian National Stock Exchange CA CAD 03. Nov 2016
OTCPK VGWC.F Common Shares Pink Sheets LLC US USD 03. Nov 2016
DB 7LV Common Shares Deutsche Boerse AG DE EUR 03. Nov 2016
Number of employees
Current staff
Staff numbers
25
Valens GroWorks employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:53
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/25
Last earnings filing: 2019/04/24
Last earnings reported: 2019/02/28
Last annual earnings reported: 2018/11/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.